Expertise in
7
conditions

Dr. Scott M. Dinehart

Dermatology
Office
15506 Highway 5 Ste A, 
Cabot, AR 
Accepting New Patients
Referral may be required
Before you request
Expertise in
7
conditions
Office
15506 Highway 5 Ste A, 
Cabot, AR 

Overview

Scott Dinehart is a Dermatologist practicing medicine in Cabot, Arkansas.

Dr. Dinehart is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Bowen's Disease, Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, and Actinic Keratosis.

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 12 clinical trials. Dr. Dinehart is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in AR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
15506 Highway 5 Ste A, Cabot, AR 72023
Other Locations
Office
9601 Baptist Health Dr Ste 860, Little Rock, AR 72205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Enrollment Status: Completed
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drug: GSK1070806
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 2
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
View 7 Less Clinical Trials

14 Total Publications

Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.
Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.
Journal: Journal of drugs in dermatology : JDD
Published: May 04, 2026
Similar Doctors
Expertise in
32
conditions
Dr. Jay A. Flaming
Dermatology
Expertise in
32
conditions
Dr. Jay A. Flaming
Dermatology
Referral may be required
Before you request

Corning Clinical Laboratories

500 S University Ave Ste 506, 
Little Rock, AR 
 (22.0 miles away)
501-664-4257
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jay Flaming is a Dermatologist practicing medicine in Little Rock, Arkansas. Dr. Flaming is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Epidermodysplasia Verruciformis, Autoerythrocyte Sensitivity, Gardner-Diamond Syndrome, and Purpura. Dr. Flaming is currently accepting new patients.

Expertise in
35
conditions
Dr. Nathan E. Lee
Dermatology
Expertise in
35
conditions
Dr. Nathan E. Lee
Dermatology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (20.8 miles away)
501-686-5356
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nathan Lee is a Dermatologist practicing medicine in Little Rock, Arkansas. Dr. Lee is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Squamous Cell Skin Carcinoma, Trichoepithelioma, Multiple Familial Trichoepithelioma, and Basal Cell Skin Cancer. Dr. Lee is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required
Before you request

Office

4200 N Rodney Parham Rd Ste 202, 
Little Rock, AR 
 (23.4 miles away)
501-227-4323
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gunnar Gibson is a Dermatologist practicing medicine in Little Rock, Arkansas. Dr. Gibson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Kaposiform Hemangioendothelioma, Fetal Cystic Hygroma, Cerebral Cavernous Malformation, and Hemangioendothelioma. Dr. Gibson is currently accepting new patients.

Frequently Asked Questions about Dr. Scott M. Dinehart

How do I make an appointment with Dr. Scott M. Dinehart?

You can book an appointment with Dr. Scott M. Dinehart by calling their office at 501-941-3101. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott M. Dinehart a top-rated expert for Bowen's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott M. Dinehart is classified as an Distinguished expert for Bowen's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott M. Dinehart specialize in?

While Dr. Scott M. Dinehart is a Dermatology, they have specific expertise in Bowen's Disease, Basal Cell Skin Cancer, and Squamous Cell Skin Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Scott M. Dinehart participate in research or clinical trials?

Yes. Dr. Scott M. Dinehart has published 14 articles and abstracts on conditions like Bowen's Disease. You can view a list of Dr. Scott M. Dinehart's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott M. Dinehart accept my insurance?

Dr. Scott M. Dinehart accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 501-941-3101 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dinehart's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile